JP2015516464A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516464A5 JP2015516464A5 JP2015512620A JP2015512620A JP2015516464A5 JP 2015516464 A5 JP2015516464 A5 JP 2015516464A5 JP 2015512620 A JP2015512620 A JP 2015512620A JP 2015512620 A JP2015512620 A JP 2015512620A JP 2015516464 A5 JP2015516464 A5 JP 2015516464A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- subject
- condition
- hsp90
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 22
- 238000000034 method Methods 0.000 claims 22
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 20
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims 20
- 230000000694 effects Effects 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- 208000009905 Neurofibromatoses Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 230000010261 cell growth Effects 0.000 claims 4
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 201000004931 neurofibromatosis Diseases 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647081P | 2012-05-15 | 2012-05-15 | |
| US61/647,081 | 2012-05-15 | ||
| PCT/US2013/000133 WO2013172872A1 (en) | 2012-05-15 | 2013-05-15 | Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516464A JP2015516464A (ja) | 2015-06-11 |
| JP2015516464A5 true JP2015516464A5 (https=) | 2016-07-14 |
Family
ID=49584102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512620A Pending JP2015516464A (ja) | 2012-05-15 | 2013-05-15 | 細胞質Ｈｓｐ９０の阻害剤としてのピリミジンジアミン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160311795A1 (https=) |
| JP (1) | JP2015516464A (https=) |
| AU (1) | AU2013263420A1 (https=) |
| CA (1) | CA2912048A1 (https=) |
| WO (1) | WO2013172872A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040807A1 (en) * | 2014-09-11 | 2016-03-17 | Calasia Pharmaceuticals, Inc. | Pyrimidine-diamine dual hsp90/trap1 inhibitors |
| CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
| CN112500402B (zh) * | 2019-09-16 | 2022-09-20 | 华东师范大学 | 一类具有抗菌活性的芳基-五元杂芳基取代的嘧啶二胺类小分子化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3873812D1 (de) * | 1987-04-07 | 1992-09-24 | Ciba Geigy Ag | 3h-1,2,3-triazolo(4,5-d)pyrimidine. |
| DE3717480A1 (de) * | 1987-05-23 | 1988-12-01 | Shell Agrar Gmbh & Co Kg | Neue herbizid und mikrobizid wirksame 2,6-diaminopyrimidine |
| AU5636900A (en) * | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| KR20060070572A (ko) * | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물 |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| DE102010050558A1 (de) * | 2010-11-05 | 2012-05-10 | Merck Patent Gmbh | 1H-Pyrrolo[2,3-b]pyridinderivate |
-
2013
- 2013-05-15 AU AU2013263420A patent/AU2013263420A1/en not_active Abandoned
- 2013-05-15 WO PCT/US2013/000133 patent/WO2013172872A1/en not_active Ceased
- 2013-05-15 JP JP2015512620A patent/JP2015516464A/ja active Pending
- 2013-05-15 CA CA2912048A patent/CA2912048A1/en not_active Abandoned
-
2015
- 2015-07-02 US US14/790,111 patent/US20160311795A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020102804A3 (en) | Pharmaceutical combination for treatment of cancer | |
| JP2012041365A5 (https=) | ||
| NZ726366A (en) | Syk inhibitors | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| MX2022008181A (es) | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. | |
| JP2016506916A5 (https=) | ||
| WO2017040993A4 (en) | Small molecule inhibitors of dyrk1a and uses thereof | |
| IN2014DN05869A (https=) | ||
| EA201690608A1 (ru) | Способы лечения раковых заболеваний | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| NZ726365A (en) | Combinations for treating cancers | |
| RU2019121667A (ru) | Аминопиразолы в качестве селективных ингибиторов янус-киназы | |
| RU2018129344A (ru) | Производное хиназолинона, способ его получения, фармацевтическая композиция и применения | |
| PE20211600A1 (es) | 2,3,5-trimetil-6-nonilclohexa-2,5-diena-1,4-diona para suprimir y tratar alfa-sinucleinopatias, tauopatias y otros trastornos | |
| JP2015516988A5 (https=) | ||
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| RU2015143106A (ru) | Терапия злокачественных опухолей | |
| JP2015516464A5 (https=) | ||
| RU2016102092A (ru) | Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2015534990A5 (https=) | ||
| PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| CN109311893A (zh) | 含有取代环戊基的吡咯并嘧啶化合物 | |
| WO2014032019A3 (en) | Compounds and methods for treating tumors | |
| RU2010150964A (ru) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам |